<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150863</url>
  </required_header>
  <id_info>
    <org_study_id>2014P000121</org_study_id>
    <nct_id>NCT02150863</nct_id>
  </id_info>
  <brief_title>Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study</brief_title>
  <official_title>Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to treat field cancerization ( pre-skin cancers) in a manner that will
      reduce the future pre-skin cancers and non-melanoma skin cancers in patients with significant
      photodamage.

      This is 3 year prospective, randomized, controlled comparison of a single treatment with
      carbon dioxide laser resurfacing vs. carbon dioxide resurfacing plus autologous epidermal
      skin graft from a non sun exposed site vs. control.

      Thirty subjects will receive treatment with each of the modalities.

      The primary measures of efficacy are (a) count of the number of actinic keratosis and non
      melanoma skin cancers, (b) blinded evaluation of severity from standard digital photographs
      taken before and after the treatments, and (c) change in histology before and after
      treatment. Safety measures include (a) pain, (b) scarring, (c) wound healing, (d) and
      infection
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty enrolling participants due to exclusion and inclusion criteria
  </why_stopped>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Count of the Number of Actinic Keratosis and Non Melanoma Skin Cancers in the Treatment Area</measure>
    <time_frame>Entire study period (3 years)</time_frame>
    <description>This is done at every visit over the 3 year period</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Extensive Photodamage</condition>
  <condition>Actinic Keratosis</condition>
  <condition>History of Numerous Skin Cancers</condition>
  <arm_group>
    <arm_group_label>Ultrapulse laser alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultrapulse laser plus Cellutome Harvesting system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrapulse Carbon Dioxide Laser</intervention_name>
    <arm_group_label>Ultrapulse laser alone</arm_group_label>
    <arm_group_label>Ultrapulse laser plus Cellutome Harvesting system</arm_group_label>
    <other_name>Lumenis Ultrapulse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellutome epidermal harvesting system</intervention_name>
    <arm_group_label>Ultrapulse laser plus Cellutome Harvesting system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Subjects with ages between 18 and 85 years, male or female.

          2. Subjects with at least 4 clinically diagnosed actinic keratoses (AKs) per treatment
             site ( up to 200 sq cm), excluding the face and neck

          3. Subjects with history of at least 1 non-melanoma skin cancer within the past year

          4. Willingness to participate in the study

          5. Informed consent agreement signed by the subject

          6. Willingness to follow the treatment schedule and post treatment care requirements

          7. Willingness to not use topical or systemic (oral) TREATMENT medications including
             imiquimod, 5-Fluorouracil, photodynamic therapy, during the treatment period.

          8. Has not had treatment for AKs in the treatment area for 4 weeks prior to enrollment

        Exclusion criteria

          1. Subjects with active skin cancer in the treatment area. Once the non-melanoma skin
             cancer has been treated, the subject can be immediately enrolled.

          2. Infection of the area to be treated

          3. An open wound in the area to be treated

          4. Presence of suntan in the area to be treated, or active tanning during the study

          5. Subjects who have taken medication known to induce photosensitivity in the previous 3
             months

          6. The patient has any contraindication to use of the carbon dioxide laser, including but
             not limited to, intake of isotretinoin in past 12 months; patients with reduced
             adnexal structures (eg, scleroderma, irradiation or burns); patients with history of
             vitiligo or psoriasis (risk of Koebnerization); history of keloids/hypertrophic
             scarring.

          7. Subject is unable to comply with treatment, home care or follow-up visits

          8. Subject is pregnant or breast feeding

          9. Prior use of topical retinoids, 5 fluorouracil, or imiquimod in treated areas within
             one month of initial treatment

         10. Prior skin treatment with laser or other devices in the treated area within two months
             of initial treatment or during the course of the study;

         11. Adverse reactions to compounds of any external agent (e.g., gels, lotions or
             anesthetic creams) required for use in the study, if no alternative to the said agent
             exists;

         12. Concurrent inflammatory skin conditions, including, but not limited to, eczema,
             contact dermatitis of any severity;

         13. Active Herpes Simplex at the time of treatment;

         14. Multiple dysplastic nevi in area to be treated;

         15. Having a bleeding disorder or taking anticoagulation medications, including heavy use
             of aspirin, in a manner which does not allow for a minimum 10 day washout period prior
             to each treatment (as per the patient's physician discretion);

         16. Significant concurrent illness, such as uncontrolled diabetes, (i.e., any disease
             state that in the opinion of the Investigator would interfere with the anesthesia,
             treatment, or healing process);

         17. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;

         18. Any condition which, in the Investigator's opinion, would make it unsafe (for the
             subject or study personnel) to treat the subject as part of this research study;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rox Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital/ Wellman Center for Photomedicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <results_first_submitted>October 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2019</results_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Richard Rox Anderson, MD</investigator_full_name>
    <investigator_title>Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT</investigator_title>
  </responsible_party>
  <keyword>actinic keratosis</keyword>
  <keyword>field cancerization</keyword>
  <keyword>organ transplant patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT02150863/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ultrapulse Laser Alone</title>
          <description>Ultrapulse Carbon Dioxide Laser</description>
        </group>
        <group group_id="P2">
          <title>Ultrapulse Laser Plus Cellutome Harvesting System</title>
          <description>Ultrapulse Carbon Dioxide Laser
Cellutome epidermal harvesting system</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>Control group, no treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There was only one patient enrolled in this study</population>
      <group_list>
        <group group_id="B1">
          <title>Ultrapulse Laser Alone</title>
          <description>Ultrapulse Carbon Dioxide Laser</description>
        </group>
        <group group_id="B2">
          <title>Ultrapulse Laser Plus Cellutome Harvesting System</title>
          <description>Ultrapulse Carbon Dioxide Laser
Cellutome epidermal harvesting system</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Control group</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Count of the Number of Actinic Keratosis and Non Melanoma Skin Cancers in the Treatment Area</title>
        <description>This is done at every visit over the 3 year period</description>
        <time_frame>Entire study period (3 years)</time_frame>
        <population>Zero participants were analyzed because no patients finished this study. Patient recruitment was very difficult for this study, and therefore the study ended prematurely.</population>
        <group_list>
          <group group_id="O1">
            <title>Ultrapulse Laser Alone</title>
            <description>Ultrapulse Carbon Dioxide Laser</description>
          </group>
          <group group_id="O2">
            <title>Ultrapulse Laser Plus Cellutome Harvesting System</title>
            <description>Ultrapulse Carbon Dioxide Laser
Cellutome epidermal harvesting system</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Control group (no laser or CelluTome)</description>
          </group>
        </group_list>
        <measure>
          <title>Count of the Number of Actinic Keratosis and Non Melanoma Skin Cancers in the Treatment Area</title>
          <description>This is done at every visit over the 3 year period</description>
          <population>Zero participants were analyzed because no patients finished this study. Patient recruitment was very difficult for this study, and therefore the study ended prematurely.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The time the patient was in the study, 6 months</time_frame>
      <desc>For areas where participants at risk is 0, it is because there were no participants in these categories.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ultrapulse Laser Alone</title>
          <description>Ultrapulse Carbon Dioxide Laser</description>
        </group>
        <group group_id="E2">
          <title>Ultrapulse Laser Plus Cellutome Harvesting System</title>
          <description>Ultrapulse Carbon Dioxide Laser
Cellutome epidermal harvesting system</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Control site</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment was very difficult for this study. Due to long study period, patient retention was also difficult. The study was terminated because of low recruitment. One subject started the study and was lost to follow-up, without completing the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Elizabeth Morehouse, Clinical Research Coordinator</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-2168</phone>
      <email>emorehouse@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

